Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Compare the DHE pharmacokinetic profiles observed following administration of:
1. MAP0004 (oral inhalation DHE)
2. MAP0004 co-administered with oral Ketoconazole
3. Intravenous (IV) DHE (D.H.E.45®, the approved reference therapy)
Compare the tolerability of MAP0004, IV DHE, and MAP0004 with co-administration of
Ketoconazole.
Phase:
Phase 1
Details
Lead Sponsor:
Allergan
Collaborator:
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan